44 results
10-K
2023 FY
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
or other assessments and our ability to claim R&D tax credits or other reliefs.
Fundraising and business development efforts may divert our management … that carries out extensive research and development (“R&D”) activities, we benefit from the U.K. HM Revenue and Customs (“HMRC”) small and medium
8-K
EX-99.1
MREO
Mereo Biopharma Group Plc
27 Mar 24
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
4:08pm
to $17.4 million in 2023. The decrease was primarily due to a $12.4 million reduction in R&D expenses for etigilimab, partially offset by an increase
6-K
EX-99.1
MREO
Mereo Biopharma Group Plc
7 Sep 23
Current report (foreign)
7:37am
Assets
Non-current
assets
Property, plant and equipment
Intangible assets
Current assets
Prepayments
R&D tax credits
Other taxes receivable
Trade
6-K
EX-99.3
MREO
Mereo Biopharma Group Plc
7 Sep 23
Current report (foreign)
7:37am
to £7.9 million for the six months ended June 30, 2023. R&D expenses relating to etigilimab decreased by £4.4 million. The decrease was primarily due … to the winding down of the open label Phase 1b/2 basket study in combination with an anti-PD-1 in a range of tumor types. R&D expenses relating
6-K
EX-99.2
MREO
Mereo Biopharma Group Plc
7 Sep 23
Current report (foreign)
7:37am
product candidates.
Research and Development (“R&D”) Expenses
Research and development expenses include:
employee-related expenses, such as salaries … and development activities, we benefit from the U.K. R&D small or medium-sized enterprise tax credit regime and are able to surrender some of our trading
6-K
EX-99.1
vj2 53j5w6v36
2 Nov 22
Current report (foreign)
4:17pm
6-K
EX-99.2
hq7jslh
2 Nov 22
Current report (foreign)
4:17pm
6-K
EX-99.2
v9rpev vgip1s
21 Oct 22
Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting
7:06am
6-K
EX-99.1
pw7tgyrn7v 7419
18 Oct 22
Mereo BioPharma Announces Updated Operating Plan to Maximize Shareholder Value
7:07am
6-K
EX-99.1
6503q9d 8lf
17 Oct 22
Mereo BioPharma Receives FDA Fast Track Designation for Alvelestat for Treatment of
7:16am
CORRESP
mh0fs6bfifk8utz0e2
19 Aug 22
Correspondence with SEC
12:00am
6-K
EX-99.1
i5ly h5fer
31 Mar 22
Mereo BioPharma Reports Full Year 2021 Financial Results and Recent Highlights
4:18pm
6-K
codasbm9vvdt5m95s6
14 Mar 22
Current report (foreign)
10:05am
6-K
EX-99.1
tsu3ef6a4d1xt dom
14 Mar 22
Current report (foreign)
10:05am
6-K
EX-99.1
uxcgglxha68kebn7
2 Nov 21
Current report (foreign)
4:16pm
6-K
EX-99.2
dtap02h4o68wq
2 Nov 21
Current report (foreign)
4:16pm
6-K
EX-99.1
pbhyuhz
20 Sep 21
Mereo BioPharma Announces Appointment of Pierre Jacquet, M.D., Ph.D. to Board of Directors
8:20am